What is Trialjectory?
Trialjectory leverages artificial intelligence (AI) to empower cancer patients, enabling them to take ownership of their treatment journey. By analyzing real-world data from its global patient community, the company provides critical insights to help patients make the most informed decisions regarding their care. This patient-centric digital health platform aims to bridge the gap in accessing advanced cancer therapies, positioning Trialjectory as a key innovator in the health-tech sector.
How much funding has Trialjectory raised?
Trialjectory has raised a total of $22.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$20M
Angel/Seed (2019): $2.7M with participation from Contour Venture Partners
Series A (2022): $20M led by Tia Ventures, Contour Venture Partners, Rho Ventures, JAL Ventures, and Insight Partners
Key Investors in Trialjectory
Contour Venture Partners
Contour Venture Partners is a seed-stage venture capital firm based in New York City, focusing on innovative software solutions within enterprise SaaS, vertical B2B SaaS, and financial services. They act as business partners, providing advice and support to help build transformative businesses.
Tia Ventures
TIA Ventures is a seed-stage venture capital fund in New York City that invests in exceptional B2B software companies. They focus on identifying product-market fit and partner with entrepreneurs dedicated to creating impactful solutions, emphasizing a customer-obsessed approach.
Rho Ventures
Rho is a venture capital firm investing in innovation since 1981, partnering with entrepreneurs to create market-defining businesses. They provide strategic value through extensive experience and focus on building sustainable businesses and facilitating valuable network connections.
What's next for Trialjectory?
With the recent major strategic investment, Trialjectory is poised for accelerated growth and expansion. The company is expected to further enhance its AI capabilities, broaden its patient community reach, and potentially forge new partnerships within the healthcare ecosystem. This latest round of financing will likely fuel the scaling of its operations, enabling Trialjectory to solidify its market position and continue its mission of democratizing access to cutting-edge cancer treatments globally. The company's trajectory suggests a focus on deepening its data analytics and patient support services.
See full Trialjectory company page
